Sequana Medical announces publication of results of multicentre randomized controlled study
Zurich, Switzerland: 19 March 2018 - Sequana Medical AG, a commercial stage medical device company and an innovator in the management of liver disease, announces the publication of a multicentre, randomized controlled study in Quality of Life Research (https://link.springer.com/journal/11136).
The study demonstrated that patients with refractory ascites treated with alfapump® system have better health-related quality of life as compared to those treated with large volume paracentesis.
In this multicentre, open-label randomized controlled trial, subjects were randomized to receive the alfapump® (AP) or large volume Paracentesis (LVP) (27 AP, 31 SoC). The SF-36v2 and CLDQ scores were compared between the two treatment arms at screening and monthly during treatment.
More info on Sequana's website.
Next > Green Biologics partners with Kingsford® Charcoal to launch new EcoLight™ natural charcoal lighter fluid
Previous > NGDATA named 2017 Tech Trailblazer for Big Data